Human Papillomavirus Genotype Specificity of Hybrid Capture 2 Low-Risk Probe Cocktail

Poljak, Mario; Kocjan, Boštjan J.; Kovanda, Anja; Lunar, Maja M.; Lepej, Snježana Židovec; Planinić, Ana; Seme, Katja; Vince, Adriana

doi:10.1128/jcm.00278-09

Cited by 11 publications

(5 citation statements)

References 24 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The possible explanation for the greater correlation of cancer development with detection and genotyping by the RFMP assay, compared to the PCR followed by oligohybridization method, could be ascribed to higher specificity and the capacity to identify a broader span of genotypes, leading to fewer positive results in controls and higher positivity in patients. Thus, the RFMP method has both greater clinical sensitivity and specificity for detecting and genotyping HPV in various levels of cervical lesions and comparable or superior analytical sensitivity for the number of HPV copies that could be detected, compared with most other reported methods [Kocjan et al, 2008; Poljak et al, 2009].…”

Section: Discussionmentioning

confidence: 99%

Analytical and clinical performances of a restriction fragment mass polymorphism assay for detection and genotyping of a wide spectrum of human papillomaviruses

Lee

Kim

Hwang

et al. 2011

Journal of Medical Virology

View full text Add to dashboard Cite

Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry-based restriction fragment mass polymorphism (RFMP) assay was adapted to human papillomavirus (HPV) genotyping. The analytical sensitivity and the clinical utility were evaluated by testing defined HPV genome equivalents and a total of 426 specimens composed of normal cytology, atypical squamous cells of undetermined significance, low grade squamous intraepithelial lesion, high grade squamous intraepithelial lesion and invasive squamous cell carcinoma. The RFMP assay was able to detect 38.4-114.6 genomic equivalents of a wide variety of HPV types. The RFMP assay detected 34 different HPV genotypes in cervical samples of which 8% were found to be multiple-type infections. The high-risk HPV positivity rate according to the histological diagnosis was 7.9% (8/101), 31.7% (38/120), 50% (55/110), 86% (37/43), 96.2% (50/52) in normal, atypical squamous cells of undetermined significance, low grade squamous intraepithelial lesion, high grade squamous intraepithelial lesion and squamous cell carcinoma subgroups, respectively. Diagnostic sensitivities/specificities for the cervical lesions of squamous cell carcinoma and high grade squamous intraepithelial lesion or worse histology were found to be 96.2%/92.1% and 91.6%/92.1%, respectively. The sensitivity, accuracy, wide range of genotype identification and high-throughput capacity with cost-effectiveness of the test consumables make the RFMP assay suitable for mass screening and monitoring of HPV-associated cervical cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Analytical and clinical performances of a restriction fragment mass polymorphism assay for detection and genotyping of a wide spectrum of human papillomaviruses

Lee

Kim

Hwang

et al. 2011

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…39,90 Cross-reaction was also detected in HC2 with low-risk HPV types (38 samples). Cross-hybridisation with both high-and low-risk HPV types has been reported with HC2, [91][92][93][94] but poses a problem for clinical management especially where HC2 gives a false-positive result. The screening programme 11.…”

mentioning

confidence: 99%

MAVARIC – a comparison of automation-assisted and manual cervical screening: a randomised controlled trial

Kitchener¹,

Blanks²,

Cubie³

et al. 2011

Clinical Governance: An International Journal

View full text Add to dashboard Cite

An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. ii ii HTA NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service' . The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for resea...

show abstract

“…For cervical swabs, DNA extraction was performed from 200 µl of non‐denatured Standard Transport Medium (STM) using QIAamp DNA Mini Kit (Qiagen, Hilden, Germany), as described previously [Poljak et al, ]. For anal swabs, total DNA was extracted from 500 µl of original sample as described previously [van Doorn et al, ].…”

Section: Methodsmentioning

confidence: 99%

Genomic diversity of low‐risk human papillomavirus genotypes HPV 40, HPV 42, HPV 43, and HPV 44

Maver

Kocjan

Seme

et al. 2013

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

In order to investigate the genomic diversity of low-risk human papillomavirus (HPV) genotypes, a total of 108 isolates of HPV 40, HPV 42, HPV 43, or HPV 44, obtained from anal swabs or tissue specimens of patients with anogenital warts, and cervical swabs of women with cervical intraepithelial neoplasia of different grades, were analyzed. The characterization of genomic variants was established by sequencing one third of the viral genome and analysis of three different genomic regions: L1, LCR, and E6. Maximum variant divergence accounted for 0.4-1.1% of the investigated genomic segments. Several novel, potentially important nucleotide substitutions, deletions, and insertions are described. Altogether, among 14 HPV 40 isolates, a total of nine different genomic variants were identified, composed of eight L1, five LCR, and four E6 genomic variants. Among 49 HPV 42 isolates, a total of 30 genomic variants were identified, composed of 20 L1, 18 LCR, and four E6 genomic variants. Among 10 HPV 43 isolates, distributed into two major genomic variant lineages with clearly defined nucleotide signatures, three genomic variants were identified, composed of three L1, two LCR, and two E6 genomic variants. Among 35 HPV 44 isolates, a total of eight HPV 44 and 11 subtype HPV 44 genomic variants were identified, composed of 13 L1, 14 LCR, and 6 E6 genomic variants. A similar level of genomic diversity of HPV 44 and its subtype was identified in our geographic region as has been reported previously on isolates collected worldwide.

show abstract

Human Papillomavirus Genotype Specificity of Hybrid Capture 2 Low-Risk Probe Cocktail

Cited by 11 publications

References 24 publications

Analytical and clinical performances of a restriction fragment mass polymorphism assay for detection and genotyping of a wide spectrum of human papillomaviruses

Analytical and clinical performances of a restriction fragment mass polymorphism assay for detection and genotyping of a wide spectrum of human papillomaviruses

MAVARIC – a comparison of automation-assisted and manual cervical screening: a randomised controlled trial

Genomic diversity of low‐risk human papillomavirus genotypes HPV 40, HPV 42, HPV 43, and HPV 44

Contact Info

Product

Resources

About